GET DAILY SIGNALSThermo Fisher Scientific (TMO) Posts Q3 Earnings Beat and Lifts Full-Year Guidance
Key Takeaways
- Adjusted EPS (earnings per share) came in at $6.68, beating the $6.40 consensus estimate by $0.28.
- Revenue rose 9% year over year to $12.14 billion, ahead of the $11.95 billion Wall Street forecast, with 6% organic growth.
- Adjusted operating margin expanded to 24.5%, up 120 basis points from 23.3% a year earlier.
- Management raised its full-year 2026 outlook to $47.7 billion–$48.2 billion in revenue and $25.13–$25.43 in adjusted EPS.
- The Laboratory Products and Biopharma Services segment led growth, while Specialty Diagnostics revenue declined 6.5%.
Earnings Context and Why It Matters
Thermo Fisher Scientific, the world's largest life sciences tools and laboratory services company, serves as a bellwether for global research and biopharma spending. Its third-quarter report matters because it signals the health of customer demand across pharmaceutical, biotech, academic, and diagnostic markets. Coming off improved end-market conditions in the prior quarter, investors were watching closely to see whether momentum could continue. The results also carry weight for the broader healthcare and life sciences tools sector, since Thermo Fisher Scientific's diversified portfolio often reflects underlying trends in drug development, lab instrumentation, and clinical diagnostics. A top-and-bottom-line beat paired with a guidance raise reinforces confidence in the company's execution.
Reported Results
For the third quarter of 2026, ended September 26, 2026, Thermo Fisher Scientific reported revenue of $12.14 billion, a 9% increase from $11.12 billion in the prior-year period and above the $11.95 billion consensus estimate. Organic revenue growth, which excludes the impact of acquisitions, divestitures, and currency translation, was 6%. To get a broader view, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
GAAP diluted EPS was $4.64, up from $4.27 a year earlier. Adjusted EPS, a non-GAAP measure that strips out one-time items such as amortization and restructuring costs, reached $6.68, exceeding the $6.40 analyst consensus. Adjusted operating income grew 15% to $2.97 billion, and the adjusted operating margin widened to 24.5% from 23.3%.
Segment performance was mixed. Laboratory Products and Biopharma Services revenue rose 15% to $6.86 billion, the largest contributor to growth. Analytical Instruments revenue increased 5.8% to $2.00 billion, and Life Sciences Solutions revenue grew 5.1% to $2.72 billion, though the latter came in slightly below analyst expectations. Specialty Diagnostics revenue declined 6.5% to $1.10 billion. The quarter also included a one-time benefit of roughly $60 million in adjusted operating income, or about $0.15 of adjusted EPS, from recovered tariff refunds.
Market Reaction and Investor Sentiment
Sentiment heading into the print was constructive, reflecting improved end-market conditions reported earlier in the year. The earnings beat on both the top and bottom lines, combined with the raised full-year guidance, generally reinforced that optimism. Analysts noted that the margin expansion and the strength in the laboratory products and biopharma services business were key positive signals. However, the weaker-than-expected results in Specialty Diagnostics and the slightly light Life Sciences Solutions revenue served as offsetting factors. The stock closed at $687.37 on the day of the report, and investor attention quickly turned to the details of the updated guidance and management's commentary on demand sustainability.
Forward Outlook and Key Factors to Monitor
Thermo Fisher Scientific raised its full-year 2026 guidance to revenue of $47.7 billion to $48.2 billion, implying 7%–8% reported growth, with organic growth now expected at 4%. The company also lifted its adjusted EPS guidance to a range of $25.13 to $25.43, representing 10%–11% growth over 2025.
Investors should watch several factors in the quarters ahead. First, the trajectory of organic revenue growth will be central, particularly whether improved customer activity in biopharma and research markets continues. Second, margin performance remains a focus, as the company leverages its PPI business system and ongoing AI deployment to drive productivity. From what I see, this is important because it shows how operational discipline can support results even in a mixed environment.
Third, the integration of recent acquisitions, including Clario, will be important for sustaining momentum and revenue synergies. Finally, the mix across segments bears monitoring, given the divergence between the strong laboratory products business and the softer diagnostics performance. Free cash flow generation, which reached $2.12 billion in the quarter, also provides a gauge of the company's financial flexibility for future capital deployment.
Using AI Tools for Deeper Sector Insights
In my own research, I frequently rely on Tickeron’s AI Screener to quickly compare companies like Thermo Fisher Scientific against peers and spot emerging patterns in the life sciences space. It helps filter for fundamentals, technical signals, and industry trends in a way that saves time while highlighting opportunities I might otherwise miss. This kind of tool has become a regular part of how I evaluate quarterly results and sector momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TMO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TMO turned positive on October 16, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TMO as a result. In 58 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 196 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 19 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.824) is normal, around the industry mean (64.051). P/E Ratio (36.936) is within average values for comparable stocks, (1.569). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties
Advertisement